206 related articles for article (PubMed ID: 24171686)
1. Atypical femoral fractures bilaterally in a patient receiving denosumab.
Drampalos E; Skarpas G; Barbounakis N; Michos I
Acta Orthop; 2014 Feb; 85(1):3-5. PubMed ID: 24171686
[No Abstract] [Full Text] [Related]
2. Atypical fracture of the femur in a patient using denosumab--a case report.
Schilcher J; Aspenberg P
Acta Orthop; 2014 Feb; 85(1):6-7. PubMed ID: 24460109
[No Abstract] [Full Text] [Related]
3. Denosumab and atypical femoral fractures.
Aspenberg P
Acta Orthop; 2014 Feb; 85(1):1. PubMed ID: 24171676
[No Abstract] [Full Text] [Related]
4. [Biphosphonate treatment can cause stress fracture. But treatment benefits significantly overweight the risk].
Sjödén G; Sayed-Noor A; Kadum B; Pettersson U
Lakartidningen; 2010 Oct 13-19; 107(41):2482-3. PubMed ID: 21137565
[No Abstract] [Full Text] [Related]
5. Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review.
Selga J; Nuñez JH; Minguell J; Lalanza M; Garrido M
Osteoporos Int; 2016 Feb; 27(2):827-32. PubMed ID: 26501556
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report.
Ramchand SK; Chiang CY; Zebaze RM; Seeman E
Osteoporos Int; 2016 Feb; 27(2):821-5. PubMed ID: 26458389
[TBL] [Abstract][Full Text] [Related]
7. Bilateral ulna fractures associated with bisphosphonate therapy.
Ang BF; Koh JS; Ng AC; Howe TS
Osteoporos Int; 2013 Apr; 24(4):1523-5. PubMed ID: 22903294
[TBL] [Abstract][Full Text] [Related]
8. Update on denosumab in postmenopausal osteoporosis--recent clinical data.
Muschitz C; Fahrleitner-Pammer A; Huber J; Preisinger E; Kudlacek S; Resch H
Wien Med Wochenschr; 2012 Sep; 162(17-18):374-9. PubMed ID: 22688622
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate-associated atypical fracture of the femur: Spontaneous healing with drug holiday and re-appearance after resumed drug therapy with bilateral simultaneous displaced fractures--a case report.
Puah KL; Tan MH
Acta Orthop; 2011 Jun; 82(3):380-2. PubMed ID: 21561306
[No Abstract] [Full Text] [Related]
10. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Josse R; Khan A; Ngui D; Shapiro M
Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
[TBL] [Abstract][Full Text] [Related]
11. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
Silverman SL; Siris E; Kendler DL; Belazi D; Brown JP; Gold DT; Lewiecki EM; Papaioannou A; Simonelli C; Ferreira I; Balasubramanian A; Dakin P; Ho P; Siddhanti S; Stolshek B; Recknor C
Osteoporos Int; 2015 Jan; 26(1):361-72. PubMed ID: 25236877
[TBL] [Abstract][Full Text] [Related]
12. Bilateral atypical femoral fractures after long-term alendronate therapy: a case report.
Bamrungsong T; Pongchaiyakul C
J Med Assoc Thai; 2010 May; 93(5):620-4. PubMed ID: 20524451
[TBL] [Abstract][Full Text] [Related]
13. Going on a drug holiday?
Bonnick SL
J Clin Densitom; 2011; 14(4):377-83. PubMed ID: 22051091
[No Abstract] [Full Text] [Related]
14. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
15. A rare case of a bisphosphonate-induced peri-prosthetic femoral fracture.
Cross MB; Nam D; van der Meulen MC; Bostrom MP
J Bone Joint Surg Br; 2012 Jul; 94(7):994-7. PubMed ID: 22733959
[TBL] [Abstract][Full Text] [Related]
16. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?
Kwek EB; Goh SK; Koh JS; Png MA; Howe TS
Injury; 2008 Feb; 39(2):224-31. PubMed ID: 18222447
[TBL] [Abstract][Full Text] [Related]
17. Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side?
Edwards MH; McCrae FC; Young-Min SA
Osteoporos Int; 2010 Apr; 21(4):701-3. PubMed ID: 19562241
[TBL] [Abstract][Full Text] [Related]
18. Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack.
Aspenberg P; Schilcher J; Fahlgren A
Acta Orthop; 2010 Aug; 81(4):460-2. PubMed ID: 20515438
[No Abstract] [Full Text] [Related]
19. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
20. Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.
Chiu WY; Lee JJ; Tsai KS
J Clin Endocrinol Metab; 2013 Apr; 98(4):E723-6. PubMed ID: 23471975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
